moneyheap
BCRX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is BioCryst Pharmaceuticals Inc (BCRX) stock moving?
BioCryst beat Q3 2026 expectations on both lines: EPS of $0.14 versus $0.08 expected, and sales of $180.3M versus $165.7M expected. Management raised FY2026 sales guidance to $715M-$730M from $690M-$715M, above the $710.1M consensus, and Wedbush kept its Outperform rating while trimming its target to $17 from $18. The shares did not hold the gain. They closed at $8.24 on Nov 4 after an intraday high of $8.86, then fell to $7.63 on Nov 5 on 15.4M shares, roughly three times the usual volume. The news set does not explain that sell-off, so it may reflect reaction to the results or to deal concerns. The stock has stayed in a tight range near $7.4-$7.7 since, with volume easing to 4.0M on Nov 10, when it closed at $7.53. On Nov 9 BioCryst agreed to acquire Astria Therapeutics for about $700M in cash and stock. The price response to that deal is already visible in the data, and the cash-and-stock structure adds dilution and integration risk. The Therapeutics Company of the Year award and the ORLADEYO and navenibart data plans are supportive but minor. Overall the fundamental news is positive, but the deal overhang and the weak price action keep the outlook mixed.
News behind the analysis
- BioCryst Pharmaceuticals to Acquire Astria Therapeutics for $700 MillionBioCryst agreed to buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million. The deal is the largest recent corporate move in the data set.
- BioCryst Pharmaceuticals Named Therapeutics Company of the YearBioCryst was named Therapeutics Company of the Year by the BioTech Breakthrough awards program. This is a recognition with no direct financial effect.
- Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17Wedbush kept its Outperform rating on BCRX after the Q3 report and lowered its price target to $17 from $18.
- Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $17Wedbush maintained its Outperform rating and trimmed its price target to $17 from $18. The target is still well above the recent share price.
- BioCryst Pharma Q3 2026 Earnings Call TranscriptManagement discussed the third-quarter 2026 results and the company's recent corporate developments on the earnings call.
- BioCryst Pharmaceuticals Reports Third Quarter 2026 Financial ResultsBioCryst reported Q3 2026 results for the quarter ended September 30, highlighting continued growth of its ORLADEYO therapy.
- BioCryst Pharma Raises FY2026 Sales Guidance from $690.000M-$715.000M to $715.000M-$730.000M vs $710.134M EstBioCryst raised its FY2026 sales guidance to $715M-$730M from $690M-$715M, above the $710.1M consensus estimate.
- BioCryst Pharma Q3 EPS $0.14 Beats $0.08 Estimate, Sales $180.292M Beat $165.674M EstimateQ3 EPS of $0.14 beat the $0.08 estimate, and sales of $180.3M beat the $165.7M estimate.
- BioCryst to Present New Data for ORLADEYO and Navenibart at ACAAI Annual Scientific MeetingBioCryst will present new clinical data on ORLADEYO and its investigational candidate navenibart at the 2026 ACAAI Annual Scientific Meeting.
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is a rare-disease biotech based in Research Triangle Park, North Carolina. Its main product is ORLADEYO (berotralstat), a once-daily pill that helps prevent attacks of hereditary angioedema (HAE), a rare genetic swelling disorder, and it is now profitable.
How it makes money
Most of its revenue comes from sales of ORLADEYO. The company expects about $625–645 million in ORLADEYO sales for 2026, out of roughly $715–730 million in total revenue. The rest comes from RAPIVAB (peramivir), an injectable flu treatment, and from licensing deals. One example is the upfront payment it received for the European rights to navenibart, a long-acting HAE drug candidate it gained when it bought Astria in early 2026.
What usually moves BCRX
- ORLADEYO prescription growth and pricing
- Competition from other HAE treatments
- Navenibart late-stage trial results and regulatory filings
- Profitability and cash-flow trends
- Takeover speculation and business-development deals